Tactile Medical targets $50M-$52M adjusted EBITDA in 2026 while maintaining $360M-$366M revenue outlook (NASDAQ:TCMD)
Tactile Systems Technology (TCMD) reported Q3 2026 revenue of $91.9M, with 13% YoY growth in lymphedema, marking five consecutive quarters of double-digit growth. The company targets $50M-$52M adjusted EBITDA and $360M-$366M revenue for 2026, according to management.
How this was made
The 30-second read
Why it matters
The earnings beat and forward guidance are likely to attract buying interest, especially from investors focused on niche medical device growth.
Market read
The earnings release provides fresh data that could move TCMD's stock in the short term.
What to watch
Potential supply chain constraints or reimbursement policy changes could affect future performance.
Background
Tactile Systems Technology, Inc. (TCMD) reported its Q3 2026 earnings, highlighting revenue growth and providing multi‑year EBITDA guidance.
Ticker impact
Q3 2026 earnings released with $91.9M revenue and 13% YoY lymphedema growth, plus 2026 adjusted EBITDA guidance of $50M-$52M.
potential upside as investors price in higher revenue growth and EBITDA guidance
The disclosed revenue and guidance are new primary information that improves the company's outlook.
Market effects
Positive signal for the medical device sector focused on lymphedema treatments.
Limited to U.S. biotech investors.
Minimal global impact beyond niche medical device investors.
Counterpoint
If guidance falls short of analyst expectations, the stock could face pressure despite revenue growth.
Key entities
- ExecutiveSheri Dodd
CEO, President & Director who delivered the earnings commentary.
